An Investment in Biotech: Part 3, page-2

Stayso,

I am surprised that GK's blog received few 'likes'. It was, in my view, a beautiful example of clearly-written text that told a compelling story. There is more to come.

Graham Kelly has spent a lot of time in the US in recent months, preparing the way for a NOX listing on Nasdaq. It is good to have him back, not least because he has an incredible ability to describe scientific developments in a way that is easily understood.

The share price dropped during his absence, despite a succession of good results, largely because of a persistent seller. I expect that trend to reverse. Graham Kelly is back in town.